Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas Schuetz will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, from 8:15 to 8:55 a.m. ET. The presentation will be virtual, with details to be updated on the company's investor webpage. Compass Therapeutics focuses on antibody-based therapeutics for cancer treatment, exploring the interplay between angiogenesis, the immune system, and tumor growth. Established in 2014 and based in Boston, Massachusetts, the company aims to advance its innovative pipeline through clinical development.
Positive
None.
Negative
None.
Insights
Analyzing...
BOSTON--(BUSINESS WIRE)--
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.
The presentation details are:
Date: Wednesday, January 12, 2022 Time: 8:15 – 8:55 a.m. ET Location: Virtual – please refer to the Investor tab on the Compass website which will be updated as details for the webcast link becomes available.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
